The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.

Start Date01 Aug 2026

Sponsor / Collaborator

Stanford University

[+3]

NCT07144956

/ Not yet recruitingPhase 3IIT

Is Adding Cilostazol to Nimodipine Improving Neurological Outcome of Patients With Aneurysmal Subarachnoid Hemorrhage? A Randomized, Double Blind, Placebo-controlled Trial

The CASH study is a randomized, double-blind, placebo-controlled trial evaluating whether adding cilostazol to standard nimodipine therapy improves neurological outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). The primary objective is to assess functional outcome at 6 months using the modified Rankin Scale. A total of 630 patients will be enrolled within 96 hours of aSAH onset and treated for 14 days. The study is conducted across 9 centers in France, funded by a PHRC, and overseen by an independent monitoring board.

Start Date15 Dec 2025

Sponsor / Collaborator

Centre Hospitalier Saint-Anne

NCT06919835

/ Not yet recruitingPhase 3IIT

CiLostAzol for pReventIon of Recurrent sTroke in Africa

Global estimates suggest that sub-Saharan Africa (SSA) now has the highest incidence, prevalence, and worst survival outcomes of stroke. With an estimated 1.4 million stroke survivors, outcomes of stroke in SSA are abysmal with 1-month case fatality at 30% and 3-year mortality rate of 84%. Stroke survivors in Africa are at an inordinately high (and worsening) risk of adverse outcomes including recurrent stroke and cardiac events over the medium- to longterm. Given the paucity of resources in the region, testing of therapies, which are potentially highly clinically efficacious and cost-effective, while developing local stroke research capacity and contributing to the global secondary stroke prevention evidence base, is urgently needed. Cilostazol, a phosphodiesterase 3 inhibitor, has shown promising efficacy and safety mainly among an Asian population by cutting risk of major adverse cardiovascular events including stroke, in half, when added to aspirin or clopidogrel (8% vs. 4%, HR 0.52, 95% CI 0.35-0.77), with no increased risk in bleeding or serious adverse events. Cilostazol's potentially strong efficacy, presumed pleiotropic effects, and relatively low cost, make it a highly appealing agent for use in stroke-prone, low-resource settings. Therefore, the overall objective of the CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-AFRICA) study is to deploy a hybrid study design to demonstrate the efficacy and safety of cilostazol twice daily in reducing MACE over 24 months vs. placebo among 1100 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, CLARITY-AFRICA also seeks to develop an implementation strategy for routine integration and policy adoption of cilostazol for post-stroke cardiovascular risk reduction in an under-resourced system. Given its compelling efficacy among a predominantly Asian population, the National Institute of Neurological Disorders and Stroke (NINDS) is poised to fund a US-based clinical trial to assess the longer-term efficacy and safety of cilostazol in a study titled CiLostAzol for pReventIon of recurrent sTroke (CLARITY). The investigators are also aware that European and Australian funding agencies are considering stroke trials of cilostazol. A concurrently executed CLARITYAfrica trial would allow recruitment of a historically underrepresented and high-risk group (Africans), test a therapy that if efficacious could be affordable for broader regional implementation, permit transcontinental mentorship/collaborations, and leverage NINDS impending investment. CLARITY-AFRICA will assess implementation outcomes such as adoption, acceptability, cost, pertinent to uptake of cilostazol in Ghana to inform policy. Regardless of its outcome, findings from CLARITYAFRICA will contribute meaningful information from the African perspective to inform the formulation of guidelines for global adoption of cilostazol into routine care for secondary CVD risk prevention by international bodies such as the World Health Organization. This application will focus on the first 2 aims of CLARITY-AFRICA to conduct the trial and assess secondary outcomes.

Start Date01 Dec 2025

Sponsor / Collaborator

Northern California Institute for Research & Education

100 Clinical Results associated with Cilostazol

100 Translational Medicine associated with Cilostazol

100 Patents (Medical) associated with Cilostazol

2,135

Literatures (Medical) associated with Cilostazol

01 Feb 2026·ATHEROSCLEROSIS

Effects of cilostazol on the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus in Korea: A nationwide population-based study

Article

Author: Hong, Sangmo ; Park, Cheol-Young ; Han, Kyungdo ; Moon, Shinje

BACKGROUND:

Cilostazol increases pain-free walking distance in patients with lower extremity peripheral arterial disease (PAD). However, the effect of cilostazol on the prognosis of PAD in patients with diabetes remains unclear. We analyzed its effects on the long-term prognosis of Korean patients with diabetes and lower extremity PAD.

METHODS:

Data of patients with diabetes and lower extremity PAD between 2009 and 2018 were collected from the Korean National Health Information Database. The primary outcome was all-cause mortality from baseline to death or until December 31, 2022. The secondary outcomes were major adverse cardiac and cerebrovascular events (MACCE) and recurrent major adverse limb events (MALEs). Multiple Cox proportional hazard regression analyses were performed.

RESULTS:

We enrolled 14,768 patients with diabetes before PAD diagnosis with complete health screening data within 2 years of PAD diagnosis (5382 patients receiving cilostazol and 9386 controls). All-cause mortality was significantly lower in patients treated with cilostazol than in the controls. Antiplatelet treatment significantly lowered the risk of all-cause mortality compared to untreated controls, although the risk reduction did not differ significantly between antiplatelet agents. However, cilostazol administration did not reduce the risk of MACCEs. Treatment with cilostazol alone or in combination with antiplatelet agents was associated with a significant reduction in recurrent MALEs, without increasing the risk of major bleeding.

CONCLUSIONS:

In patients with diabetes and lower extremity PAD, cilostazol may improve the prognosis without increasing the risk of bleeding. These findings provide epidemiological evidence for better PAD outcomes in patients with diabetes, although further research is required to elucidate the underlying mechanisms.

01 Feb 2026·CURRENT OPINION IN NEUROLOGY

Precision medicine in Moyamoya vasculopathy

Review

Author: Patel, Ritik ; Mendoza, Johnny A. ; Krittanawong, Chayakrit ; Memon, Muhammad ; Tangsrivimol, Jonathan A. ; Qadeer, Yusuf K.

Purpose of review:

Moyamoya vasculopathy is a progressive cerebrovascular steno-occlusive disease with variable presentation. As revascularization techniques, antiplatelet therapies, and imaging-based artificial intelligence (AI) diagnostics continue to advance, there is an emerging opportunity to refine patient stratification by integrating genetic profiling, neuroimaging phenotypes, and circulating biomarkers.

Recent findings:

The RNF213 locus (particularly p.R4810K) represents the primary susceptibility allele in East Asian cohorts, with secondary contributors including ACTA2 and GUCY1A3 showing incomplete penetrance. Emerging. data reveal dysregulated lipid metabolism, impaired arginine–arginine-nitric oxide (NO) and methionine signaling, heightened oxidative stress, and ferroptotic pathways. Proteomic studies identify disrupted angiogenic and cytoskeletal programs with potential biomarker utility in cerebrospinal fluid and serum. Current diagnostic standards employ MRI/MRA and digital subtraction angiography. Observational data support antiplatelet agents, including cilostazol, in reducing stroke recurrence and mortality. Direct and combined bypass approaches demonstrate superior outcomes in adult hemorrhagic disease, whereas indirect revascularization predominates in pediatric populations. Emerging AI-integrated diagnostic algorithms incorporating imaging and multiomic data exhibit promising diagnostic accuracy.

Summary:

Systematic integration of genotypic and multiomic profiling with hemodynamic assessment could enhance prognostic precision, optimize surgical timing, and guide antiplatelet selection in Moyamoya. Next step priorities include studying ethnically diverse multicenter registries and rigorous trials evaluating targeted and regenerative therapeutic strategies. Digital subtraction angiography (DSA)-guided diagnosis and individualized revascularization strategies remain the clinical standard.

01 Jan 2026·JOURNAL OF CLINICAL NEUROSCIENCE

Dual antiplatelet therapy guided by CYP2C19 polymorphism after intracranial or extracranial stenting: A single-center retrospective cohort study

Article

Author: Mengchi, Pu ; Qingyu, Fan ; Hong, Fan ; Ye, Li ; Guilian, Zhang ; Fangcun, Li

OBJECTIVE:

To evaluate the efficacy and safety of three distinct dual antiplatelet therapy (DAPT) strategies following intracranial and extracranial neurovascular stenting. under the guidance of CYP2C19 genotyping.

METHODS:

In this single-center, retrospective cohort study, consecutive patients who underwent elective neurovascular stenting in the Department of Neurology, Second Affiliated Hospital of Xi'an Jiaotong University, from January 2020 to December 2024 and completed 90-day follow-up were retrospectively enrolled. All patients received DAPT for 90 days (starting 3 days before the procedure). In Part I, patients were stratified into a genotype-guided group (n = 938) and a conventional group (n = 218) according to whether CYP2C19 genotyping was performed. In the genotype-guided group, CYP2C19 rapid metabolizers received clopidogrel (75 mg qd) plus aspirin (100 mg qd), whereas intermediate or poor metabolizers received ticagrelor (90 mg bid) or cilostazol (100 mg bid) plus aspirin (100 mg qd). The conventional group received clopidogrel plus aspirin. The primary efficacy outcome was new ischemic stroke within 90 days. In Part II, genotype-guided patients were further classified into clopidogrel, ticagrelor, and cilostazol subgroups, all combined with aspirin. The primary efficacy endpoint remained 90-day ischemic stroke; the primary safety endpoint was moderate-to-severe bleeding within 90 days.

RESULTS:

Of 1,270 included patients, 1,156 completed 90-day follow-up. Baseline characteristics were balanced between the genotype-guided and conventional groups (all P > 0.05). The 90-day ischemic stroke rate was significantly lower with genotype-guided therapy (3.73 % vs 6.88 %; P = 0.039). Within the genotype-guided cohort, baseline variables were balanced across clopidogrel (n = 386), ticagrelor (n = 330), and cilostazol (n = 222) subgroups (all P > 0.05). A significant difference in ischemic stroke rates was observed among the three DAPT regimens (P = 0.034), forming an efficacy gradient: clopidogrel in rapid metabolizers (2.33 %), ticagrelor (3.63 %), and cilostazol (5.96 %). Post-hoc analysis showed a higher risk with cilostazol versus clopidogrel (relative risk 2.55; P = 0.0097). The incidence of moderate-to-severe bleeding was similar low across all groups (clopidogrel 0.42 %, ticagrelor 0.61 %, cilostazol 0.33 %; P > 0.05), However, ticagrelor was associated with a significantly higher rate of any bleeding event (7.27 %) compared to both clopidogrel (2.33 %) and cilostazol (0.99 %). Multivariable analysis established the DAPT regimen as an independent predictor of ischemic stroke.

CONCLUSIONS:

CYP2C19 genotype- DAPT significantly reduces the risk of ischemic stroke within 90 days after intracranial or extracranial stenting. For CYP2C19 loss-of-function allele carriers, ticagrelor plus aspirin offers a more effective antithrombotic effect compared to cilostazol plus aspirin, albeit with a higher risk of manageable bleeding events. An individualized strategy is recommended: ticagrelor should be prioritized for ischemic prevention in most patients, while cilostazol represents a safer alternative for those at very high bleeding risk.

News (Medical) associated with Cilostazol

28 May 2024

·www.prnewswire.com

Genovate Announces Plans to Submit a New Drug Application for PMR to the U.S. Food & Drug Administration in the Second Half of 2025

TAIPEI, May 28, 2024 /PRNewswire/ -- Genovate Biotechnology Co., Ltd. (TPEx: 4130), a Taiwan-based specialty pharmaceutical company, today announced its plans to submit a New Drug Application (NDA) with the United States Food and Drug Administration (US FDA) for PMR, an investigational once daily extended-release form of cilostazol for the treatment of Intermittent Claudication, in the second half of 2025. In the written responses to the pre-NDA meeting package, the FDA confirmed that the clinical studies conducted are sufficient to support the submission of a marketing application under the 505(b)(2) regulatory pathway. The key study in the submission package, GBL23-001 (NCT06167265), is a randomized, fully replicate crossover study designed to evaluate the bioequivalence and within-subject variability between PMR 145 mg once daily and the immediate-release tablet of cilostazol 100 mg twice daily. This study is expected to be completed in mid-2024, and the top-line results have shown that the primary endpoints of the study were achieved, and the decision to submit the application was made following the successful outcome of study GBL23-001. Furthermore, Genovate has been improving the PMR formulation and its manufacturing processes in order to address additional FDA comments. All clinical study and manufacturing data are expected to be included in the final submission package. "We are pleased to share what we believe is an efficient regulatory pathway for PMR with the goal of bringing a new treatment option to the people who suffer from intermittent claudication and recurrence of cerebral infarction, from the US to the globe." said Chia-Chen Chu, General Manager of Genovate. About PMR (Cilostazol Extended-Release Tablets) PMR, a novel extended-release (ER) formulation of cilostazol, was designed to reduce the concentration-dependent side effects associated with immediate-release (IR) tablet form of cilostazol. Cilostazol is currently available in IR tablet form at 50 and 100 mg strengths administered twice daily. The IR formulation of cilostazol, marketed as Pletal® in the US (Pletaal® in Taiwan and other Asian countries), was first available in Japan in 1988 for the treatment of peripheral arterial diseases and the prevention of recurrence of cerebral infarction and later approved by the US FDA in 1999 for the treatment of intermittent claudication (IC). Cilostazol is a specific PDE III inhibitor that can cause reduced platelet aggregation and increased vasodilatation. Cilostazol showed good efficacy in preventing secondary strokes, notably reducing the rates of ischaemic stroke recurrence. Nevertheless, the results from eight placebo-controlled clinical trials indicated that 15.4% of patients withdrawn from cilostazol treatment were as a result of adverse reactions. Headache, palpitations, and diarrhea were the most frequently reported adverse reactions among these patients. These adverse reactions were attributable to the peak concentration of cilostazol. Genovate is developing an ER tablet form of cilostazol, PMR, to be administered once daily aiming to improve adherence and to reduce the side effects associated with the high peak-to-trough variation of the concentration of cilostazol IR. About Intermittent Claudication Peripheral arterial disease (PAD) affects over 200 million people globally and around 8.5 million Americans over the age of 40. PAD occurs as a result of the narrowing or blockade of blood vessels that carry blood from the heart to the legs. The main symptom of PAD observed in approximately 70% of patients is intermittent claudication (IC), a condition that presents as pain and cramping in the lower extremities (thigh, calf, hip and buttock muscles), as a result of limited blood flow. IC is commonly viewed as a signal of substantial atherosclerosis, suggesting a higher likelihood of heart attack or stroke. The symptoms of IC are intermittent, exacerbated when walking or during exercise, and are alleviated with rest, but reoccur when activity resume; as a result, IC can be very debilitating, drastically affecting the quality of life of those affected. In severe cases, IC may require surgical intervention, but in general, it can be treated and managed with a combinational approach including medication, life style changes that modify or eliminate risk factors, and exercise program. Drugs improving blood flow such as anti-clotting agents (aspirin), anti-hypertensives, statins, and phosphodiesterase (PDE) III inhibitors such as cilostazol are currently used to treat IC. About Genovate Biotechnology Co., Ltd. Genovate Biotechnology Co., Ltd. is a Taiwan-based, fully integrated specialty pharmaceutical company focusing on the new drug development in new formulation, new active ingredient, new treatment modality in cardiovascular, autoimmune, neurodegenerative, and liver diseases. Genovate is equipped with PIC/S GMP manufacturing, marketing, and distribution capabilities. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of any regulatory process or ultimate approvals for PMR for the treatment of IC. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with the projected timeline of our NDA submission, whether FDA will agree with our interpretation of the data or the adequacy of data to support an NDA, the FDA's review of our NDA, market conditions, as well as risks and uncertainties inherent in Genovate's business. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. SOURCE Genovate Biotech

Drug ApprovalClinical ResultNDA

24 May 2024

·www.pharmaceutical-technology.com

Biocon and Handok link to commercialise Liraglutide in South Korea

Biocon will handle Liraglutide’s development, manufacturing and supply. Credit: Poetra.RH / Shutterstock.com. Indian biopharmaceutical company Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea. A vertically integrated, complex drug, Liraglutide is administered using pre-filled injection pens. It is designed for chronic weight management alongside a reduced-calorie diet and increased physical activity. Biocon will handle Liraglutide’s development, manufacture and supply in South Korea. Handok will oversee the regulatory approvals and commercialisation of the product in the market. Handok’s diabetes care portfolio includes Amaryl, Tenelia and the real-time glucose monitoring device Barozen Fit. See Also: Alvotech and Dr Reddy’s partner to commercialise AVT03 (Cilostazol + rosuvastatin) by Korea United Pharm for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval Global contract research organisation IQVIA ‘s moving annual total for the fourth quarter of 2023 values the market opportunity for Liraglutide in South Korea at $47m. Biocon CEO and MD Siddharth Mittal stated: “We are pleased to enter into this strategic partnership with Handok, which will enable patients in South Korea dealing with weight management to gain access to our GLP-1 peptide drug product, synthetic Liraglutide. “This also aligns with our commitment to expand our portfolio of innovative, affordable medicines to address the unmet needs of patients around the world. We look forward to leveraging Handok’s strong capabilities to help patients in the region better manage their disease.” In December 2023, Biocon’s subsidiary Biocon Biologics completed the integration of Viatris’ biosimilars business across 31 European countries.

License out/inDrug Approval

13 Dec 2023

·synapse.patsnap.com

What are PDE3 inhibitors and how do you quickly get the latest development progress?

PDE3, or phosphodiesterase 3, is an enzyme found in the human body that plays a crucial role in regulating cellular signaling pathways. Specifically, PDE3 is responsible for breaking down cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are important secondary messengers involved in various physiological processes. By inhibiting PDE3 activity, certain medications can increase the levels of cAMP and cGMP, leading to vasodilation, increased contractility of cardiac muscles, and platelet aggregation inhibition. This makes PDE3 an important target for pharmaceutical interventions aimed at treating cardiovascular diseases, such as heart failure and hypertension. The future of PDE3 inhibitors is promising. An agent that selectively inhibits sarcoplasmic reticulum-associated PDE3A-136 may help to preserve intracellular Ca2+ cycling and contractility in patients with dilated cardiomyopathy taking β-adrenergic receptor agonists. This may reduce arrhythmogenic effects attributable to increases in cytosolic cAMP content. Furthermore, given the promising results in preclinical models, numerous clinical trials have evaluated the therapeutic efficacy of PDE3 inhibitors against depression in humans. Therefore, the development of PDE3 inhibitors presents opportunities for innovation and competition in the pharmaceutical industry. The analysis of the target PDE3 reveals a competitive landscape with multiple companies actively involved in research and development. The highest stage of development is the "Approved" phase, indicating successful drug development in various indications. Small molecule drugs are progressing rapidly, with a significant number of approved and inactive drugs. China, Japan, the United States, and the European Union are leading in terms of drug development under the target PDE3. The future development of the target PDE3 is promising, with ongoing research and development efforts by various companies and countries/locations. How do they work?PDE3 inhibitors are a type of drug that target and inhibit the enzyme phosphodiesterase 3 (PDE3). Phosphodiesterases are a group of enzymes that play a crucial role in regulating cellular signaling pathways by breaking down cyclic nucleotides, specifically cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). In the context of biomedicine, PDE3 inhibitors are primarily used as cardiovascular drugs. They work by blocking the activity of PDE3, which leads to increased levels of cAMP and cGMP in cells. This, in turn, promotes vasodilation (relaxation of blood vessels), inhibits platelet aggregation (clumping of blood platelets), and reduces smooth muscle cell proliferation. These effects contribute to the treatment of conditions such as heart failure, angina (chest pain), and peripheral vascular disease. By inhibiting PDE3, these drugs enhance the effects of the cyclic nucleotides, which are important secondary messengers involved in various cellular processes. The increased levels of cAMP and cGMP can have beneficial effects on cardiac function, blood flow, and overall cardiovascular health. It's worth noting that PDE3 inhibitors may have side effects, including increased heart rate, arrhythmias, and potential interactions with other medications. Therefore, their use should be carefully monitored and prescribed by healthcare professionals. List of PDE3 InhibitorsThe currently marketed PDE3 inhibitors include: Cilostazol/ginkgo-bilobaLevosimendanEnoximoneAnagrelide HydrochlorideCilostazolOlprinone Hydrochloride HydrateIbudilastInamrinone LactateEnsifentrineCilostazol/DecanolFor more information, please click on the image below. What are PDE3 inhibitors used for?PDE3 inhibitors are under investigation for indications that include heart failure, angina (chest pain), and peripheral vascular disease. For more information, please click on the image below to log in and search. How to obtain the latest development progress of PDE3 inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of PDE3 inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 Deals associated with Cilostazol

External Link

KEGG	Wiki	ATC	Drug Bank
D01896	Cilostazol	B01AC23	DB01166

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Brain Infarction	Japan	Otsuka Pharmaceutical Co., Ltd.	15 Mar 2007
Peripheral Vascular Diseases	Brazil	Libbs Farmacêutica Ltda.	05 Jun 2002
Stroke	Brazil	Libbs Farmacêutica Ltda.	05 Jun 2002
Intermittent Claudication	United States	Otsuka Pharmaceutical Co., Ltd.	15 Jan 1999
Arterial Occlusive Diseases	China	Zhejiang Otsuka Pharmaceutical Co. Ltd.	01 Jan 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Angina Pectoris, Variant	Phase 3	South Korea	Korea Otsuka Pharmaceutical Co., Ltd.	01 Nov 2013
Tinnitus	Clinical	South Korea	Korea Otsuka Pharmaceutical Co., Ltd.	01 Jul 2011
Chemical and Drug Induced Liver Injury	Preclinical	Egypt	Badr University In Cairo	09 Apr 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06242145 (Pubmed \| Neurol Sci)	Phase 3	Acute Ischemic Stroke	580	Cilostazol	qeqrgftdmg(svwqrmofjy) = eykdlhenad pohteojnyj (xtzgnlpcld )	Positive	15 Apr 2025
				Clopidogrel	qeqrgftdmg(svwqrmofjy) = tlkszkrpyr pohteojnyj (xtzgnlpcld )
NCT06242132 (CILO-CLOP Trial, Pubmed \| Neurol Ther)	Phase 3	Acute Ischemic Stroke hypertension	870	Cilostazol	ziwnrcmvmq(hkluozrxks) = okkzhrkwci fshczznqkg (aaniajtzjf )	Positive	12 Apr 2025
				Clopidogrel	ziwnrcmvmq(hkluozrxks) = ktupvsxxta fshczznqkg (aaniajtzjf )
NCT01261234 (Randomized Controlled Trial of Cilostazol Addition for In-Stent Restenosis After Carotid Artery Stenting, Pubmed \| Stroke)	Not Applicable	Vascular restenosis	631	Cilostazol 50 mg	nbwvpllfwl(xujzdndfoh) = histlnrbbo ejrmnffmjc (bmnrzbxaom ) View more	Positive	01 Dec 2024
				No Cilostazol	nbwvpllfwl(xujzdndfoh) = mbkuinigvp ejrmnffmjc (bmnrzbxaom ) View more
NCT05126836 (CLIP-HFpEF, Pubmed \| ESC Heart Fail)	Phase 2	Heart Failure, Diastolic	23	Cilostazol	wmelwqddcm(zmikymlyrf) = cxhihxivgx wmpymbkygd (dydbztifnk, 68 - 974) View more	Positive	17 Nov 2024
				Placebo	wmelwqddcm(zmikymlyrf) = cenmaefhkf wmpymbkygd (dydbztifnk, 154 - 1056) View more
NCT03451591 (LACI-2, CTgov)	Phase 2/3	Stroke, Lacunar	363	Isosorbide Mononitrate (Isosorbide Mononitrate XL (ISMN))	ctyfnqzbjq = uqubigaysh svnilwvqgb (sltvzkwdvm, ewpkaibaih - lvidqhoueu) View more	-	12 Nov 2024
				Cilostazol (Cilostazol)	ctyfnqzbjq = lmcapuaqgy svnilwvqgb (sltvzkwdvm, gnrqnaweln - hesyhhrxpu) View more
NCT05126836 (CLIP-HFpEF, CTgov)	Phase 2	Heart failure with normal ejection fraction \| Heart Failure, Diastolic	25	Placebo+Cilostazol 100Mg Tab (Cilostazol)	siopiccyah(udbkppxvor) = qfgwepxyzd ysdslnfapp (fmugmzpcxb, mvrucwadbt - chehlaygey) View more	-	15 Dec 2023
				Placebo+Cilostazol 100Mg Tab (Placebo)	siopiccyah(udbkppxvor) = liiejxmaip ysdslnfapp (fmugmzpcxb, wdphhxqldv - fliqpowdwn) View more
ESC2023	Phase 4	ST Elevation Myocardial Infarction	985	DAT (aspirin and clopidogrel for 12 months)	qxsikuhmap(zdboxozfbu) = xuzflbmycv dyhlxcegwa (gnguufqbge )	Negative	25 Aug 2023
				TAT 1M (aspirin, clopidogrel, and cilostazol for 1 month)	qxsikuhmap(zdboxozfbu) = wtrnvxworj dyhlxcegwa (gnguufqbge )
NCT01995370 (CSPS.com, Pubmed \| Stroke)	Phase 4	Stroke, Lacunar	925	DAPT group receiving cilostazol and either aspirin or clopidogrel	voeqhnfbyx(ngxhvlanmt) = zrcjvyvyry wtxfgcqvmv (ihkicupsqv )	Positive	03 Feb 2023
				SAPT group receiving aspirin or clopidogrel alone	voeqhnfbyx(ngxhvlanmt) = okwfuxwbbz wtxfgcqvmv (ihkicupsqv )
NCT01995370 (CSPS.com, Pubmed \| Int J Stroke)	Not Applicable	Stroke \| Constriction, Pathologic	-	DAPT with cilostazol plus aspirin or clopidogrel	hdetchkwym(ttwoawapvm): HR = 0.79 (95% CI, 0.27 - 2.26) View more	-	28 Jun 2022
				Aspirin or clopidogrel alone
NCT01995370 (CSPS.com Trial, Pubmed \| Neurology)	Phase 4	Stroke	1,879	Cilostazol with aspirin or clopidogrel	pbjyjqytwc(lfqmgxgzfo) = ewaamsfrma czdkhfjzzp (wmyinuzgai )	Positive	08 Mar 2022
				Aspirin or clopidogrel alone	pbjyjqytwc(lfqmgxgzfo) = qceqavzhrc czdkhfjzzp (wmyinuzgai )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis